Targeted Delivery of Dasatinib to Deplete Tumor-Associated Macrophages by Mannosylated Mixed Micelles for Tumor Immunotherapy
Targeted Delivery of Dasatinib to Deplete Tumor-Associated Macrophages by Mannosylated Mixed Micelles for Tumor Immunotherapy
复制标题
通过甘露糖化混合胶束靶向递送达沙替尼以消耗肿瘤相关巨噬细胞，用于肿瘤免疫治疗
DOI：
10.1021/acsbiomaterials.0c01046
复制
发表时间：
2020
影响因子：
5.8
通讯作者：
Chen Dawei
中科院分区：
文献类型：
--
作者：
Zhang Xiaoxu;Zang Xinlong;Qiao Mingxi;Zhao Xiuli;Hu Haiyang;Chen Dawei
肿瘤相关巨噬细胞（TAM）在肿瘤中大量存在，主要表现为促进肿瘤进展的促肿瘤M2型。TAM的特异性消耗对于抗肿瘤治疗是有利的。在这项研究中，开发了甘露糖基化混合胶束（DAS-MMic），以特异性地递送达沙替尼（DAS），从而消除用于肿瘤免疫治疗的TAM。体外和体内实验结果表明，DAS-MMic可以有效地清除TAM，减少血管生成，重新编程免疫抑制肿瘤微环境，并最终抑制肿瘤进展。这些数据表明通过DAS-MMic直接消除TAMS用于肿瘤免疫治疗的潜力。
Tumor-associated macrophages (TAMs) are abundant in tumors and predominately show protumor M2-type fostering tumor progression. Specific depletion of TAMs is conceivably favorable for antitumor therapy. In this study, mannosylated mixed micelles (DAS-MMic) were developed to specifically deliver dasatinib (DAS) to eliminate TAMs for tumor immunotherapy. In vitro and in vivo results showed that DAS-MMic could effectively eradicate TAMs, decrease angiogenesis, reprogram the immunosuppressive tumor microenvironment, and finally suppress tumor progression. These data suggest the potential of direct elimination of TAMS by DAS-MMic for tumor immunotherapy.